key: cord-1003292-ae0fxg9o authors: Zhu, Ling; Deng, Yong-Qiang; Zhang, Rong-Rong; Cui, Zhen; Sun, Chun-Yun; Fan, Chang-Fa; Xing, Xiaorui; Huang, Weijin; Chen, Qi; Zhang, Na-Na; Ye, Qing; Cao, Tian-Shu; Wang, Nan; Wang, Lei; Cao, Lei; Wang, Huiyu; Kong, Desheng; Ma, Juan; Luo, Chunxia; Zhang, Yanjing; Nie, Jianhui; Sun, Yao; Lv, Zhe; Shaw, Neil; Li, Qianqian; Li, Xiao-Feng; Hu, Junjie; Xie, Liangzhi; Rao, Zihe; Wang, Youchun; Wang, Xiangxi; Qin, Cheng-Feng title: Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2 date: 2020-11-24 journal: bioRxiv DOI: 10.1101/2020.11.24.393629 sha: 29936e50c8982f1029953d059e40cbc88e22d421 doc_id: 1003292 cord_uid: ae0fxg9o Receptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10-fold of effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the RBD, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19. Highlights SARS-CoV-2 specific antibody, HB27, blocks viral receptor binding and membrane fusion HB27 confers prophylactic and therapeutic protection against SARS-CoV-2 in mice models Rhesus macaques showed no adverse side effects when administered with HB27 Cryo-EM studies suggest that HB27 sterically occludes SARS-CoV-2 from its receptor Keywords: SARS-CoV-2, COVID-19, in vivo protection, preclinical safety evaluation, 49 human neutralizing antibody, immuno-therapy, Cryo-EM structure. and Table S1 ). Notably, prophylactic and therapeutic 192 efficacy of HB27 in animal models revealed that >99.9% of the viral RNA loads in the 193 lungs and trachea could be reduced at 5 days post infection ( Figure 2) , suggesting that 194 a half-life of 10 days for HB27 is probably sufficient for deriving therapeutic benefit. Details of the results of the measurements of toxicokinetic parameters are presented in 196 Table S1 . These results suggest that HB27 probably has pharmacokinetic properties 197 consistent with a typical human IgG1. Hematological and biochemical analysis, To evaluate the ability of HB27 to inhibit binding of RBD to ACE2, we performed 206 competitive binding assays at both protein and cellular levels. Results of the enzyme-207 linked immunosorbent assay (ELISA) revealed that HB27 could prevent the binding of 208 soluble ACE2 (monomer in solution) to SARS-CoV-2 RBD with an EC50 value of 0.5 209 nM ( Figure S2A ). To verify the ability of HB27 to block the binding of ACE2 to 210 trimeric S, we expressed and purified stabilized SARS-CoV-2 S ectodomain trimer. Surface plasmon resonance (SPR) assays indicated that HB27 interacts with SARS- To delineate the structural basis for HB27-mediated specific neutralization, we 284 determined the cryo-EM structure of a prefusion stabilized SARS-CoV-2 S ectodomain 285 trimer in complex with the HB27 Fab fragment using single particle reconstruction. Table S2 ). The initial maps for the binding interface between RBD and HB27 were 293 relatively weak due to conformational heterogeneity, which is in line with the structural 294 observations of stochastic RBD rotations at different angles while switching from the 295 "closed" to "open" states ( Figure 6B -6C). In order to improve the local resolution, we 296 employed a "block-based" reconstruction approach, which resulted in a 3.9 Å resolution, Figure 6F ). The heavy and light chains bury ~500 Å 2 and ~210 Å 2 of the surface area 304 of the epitope, respectively. Tight binding is further facilitated by 5 hydrogen bonds 305 ( Figure 6G and Table S3 ). HB27 epitope includes 12 residues, of which only 7 residues 306 are conserved between SARS-CoV-2 and SARS-CoV, explaining its specificity for 307 SARS-CoV-2 for binding and neutralization ( Figure S5A ). Although a number of point 308 mutations in the RBD have been reported in currently circulating strains, none of these 309 mutations lie within the HB27 epitope ( Figure S5A ). To test the spectrum of Our results indicate that HB27 probably inhibits SARS-CoV-2 infection at multiple 373 steps during the viral entry process. First, viral infection can be stalled by hindering the 374 attachment of SARS-CoV-2 to host cells by preventing interactions between the RBD Upon virus attachment and entry into host cells, proteolytic activation at the S1/S2 377 boundary leads to S1 dissociation and a dramatic structural change in S2, which triggers See also Figure S1 . See also Table S1 . Detailed informatin of the data sets and refinement statistics are summarized in Table 846 S2. Surface plasmon resonance 848 The SARS-CoV-2 S trimer was immobilized onto a CM5 sensor to ~500 response units Images were recorded using Olympus BX51 microscope equipped with a DP72 camera. Towards automated 916 crystallographic structure refinement with phenix. refine Potent neutralizing antibodies from COVID-920 19 patients define multiple targets of vulnerability Tools for 922 macromolecular model building and refinement into electron cryo-microscopy reconstructions Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-926 cell sequencing of convalescent patients' B cells MolProbity: all-atom structure validation for 929 macromolecular crystallography Prophylactic and postexposure efficacy of a 933 potent human monoclonal antibody against MERS coronavirus Cryo-electron 945 microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational 946 state for receptor binding Studies in humanized mice and convalescent humans yield a SARS-CoV-2 949 antibody cocktail SARS-CoV-2 Cell Entry Depends on ACE2 and 952 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Pre-fusion structure of a human coronavirus 955 spike protein Spike mutation pipeline reveals the emergence of a more 958 transmissible form of SARS-CoV-2. bioRxiv : the preprint server for biology Quantifying the local resolution of cryo-EM 960 density maps Structure, Function, and Evolution of Coronavirus Spike Proteins Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus 965 origins and receptor binding Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerging 968 microbes & infections 9 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-971 reactivity with SARS-CoV Immunogenicity and structures of a rationally designed 974 prefusion MERS-CoV spike antigen Processing of Structurally Heterogeneous Cryo-EM Data in RELION Prevention of overfitting in cryo-EM structure determination Cell entry mechanisms 990 of SARS-CoV-2 A 993 human neutralizing antibody targets the receptor binding site of SARS-CoV-2 A Mouse Model of SARS-CoV-2 Infection and Pathogenesis Antigenicity of the SARS-CoV-2 Spike Glycoprotein Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion Unexpected Receptor Functional Mimicry Elucidates Activation 1004 of Coronavirus Fusion Structures of the portal vertex reveal essential protein-protein interactions for Herpesvirus 1007 assembly and maturation Architecture of African swine fever virus and implications for viral assembly Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the 1013 receptor recognition site Broad neutralization of SARS-related viruses by 1017 human monoclonal antibodies Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Inhibition 1025 of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion 1026 inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Architecture 1029 of the herpesvirus genome-packaging complex and implications for DNA translocation A highly 1032 conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV Gctf: Real-time CTF determination and correction Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody A pneumonia outbreak associated with a new coronavirus of probable bat origin Potently neutralizing and protective human antibodies against SARS-1046 Zihe Rao 1 *, Youchun Wang 5 *, Xiangxi Wang 1,8,11 * and Cheng-Feng Qin 2 * Figure S1 Murine antibody mhB27 strongly binds SARS-CoV-2 RBD and 1094 neutralizes SARS-CoV-2 PSV. Related to Figure 1. 1095 (A) Binding assay of mhB27 to SARS-CoV-2 RBD. mhB27 was serial diluted and 1096 tested its ability to bind to SARS-CoV-2 RBD by ELISA Neutralizing activities of mhB27 against SARS-CoV-2 pseudoviruses (PSV) HB27 was demonstrated to compete with recombinant ACE2 for binding to SARS CoV-2 RBD with an EC50 value of 0.5 nM by the enzyme-linked immunosorbent assay BIAcore SPR kinetic profile of SARS-CoV-2 S trimer and HB27. The binding 1129 affinity KD (equilibrium dissociation constant, KD = Kd/Ka, where Kd and Ka represent 1130 the dissociation rate constant and association rate constant, respectively) values were 1131 obtained using a series of HB27 concentrations and fitted in a global mode in each 1132 sensorgram BIAcore SPR kinetic profiles of SARS-CoV-2 RBD (left panel) and S trimer (right 1134 panel) with ACE2. The binding affinity KD (equilibrium dissociation constant where Kd and Ka represent the dissociation rate constant and association rate 1136 constant, respectively) values were obtained using a series of HB27 concentrations and 1137 fitted in a global mode in each sensorgram D) Competition of HB27 for SARS-CoV-2 RBD binding to 293T cells expressing 1139 GFP-tagged ACE2 as detected by immunofluorescence assay, scale bar, 100 μm Figure S3 Characterization of SARS-CoV-2 and HB27, and cryo-EM maps and 1164 atomic models of SARS-CoV-2 S and HB27 complex SDS-PAGE analysis of the SARS-CoV-2 S trimer, the HB27 IgG and the Fab (n=2) SD Notes: 1235 t1/2: half time (or half life) Tmax: time at maximum concentration 1237 Cmax: maximum concentration AUClast: area under the concentration-time curve from time zero to the last time point 1239 Vd: volume of distribution Cl: plasma clearance 1241 MRT: mean residence time